Middle & East Africa Cancer Vaccine Market - Segmented by type, technology, end-user and geography (2016 - 2021)

  • ID: 3784805
  • Report
  • Region: Africa, East Africa, Middle East
  • 82 pages
  • Mordor Intelligence
1 of 5


  • Aduro Biotech
  • Cytos
  • GlaxosmithKline
  • Medimmune
  • Oxford Biomedica
  • Sanofi
  • MORE
Cancer vaccines are biological preparations that stimulate or strengthen a person's immune system against cancer. Cancer vaccines are usually administered intravenously. They can be used for both adults and children. The vaccines can be broadly classified into prophylactic and therapeutic vaccines. Prophylactic vaccines are used for the prevention of cancer, whereas therapeutic vaccines are used for treatment of the disease. Analysts forecast the Middle East & Africa cancer vaccines market to grow at a CAGR of 20-25% over the period 2015-2020. The Middle East & Africa market is currently estimated to be valued at USD 41 million for the year 2015.

The market for cancer vaccines is much smaller than other cancer therapeutic categories. The size of the market can be attributed to the nascent stages of industry life cycle and the late introduction of the vaccines in the market. To tap this market, many companies from the MEA region are actively investing in cancer vaccine development. The market penetration is expected to increase with the increase in competition among the various pharmaceutical companies to obtain a larger portion of this market.

The Middle & East Africa Cancer Vaccines Market is segmented based on:

- Technology
- Subunit Vaccines
- Live Attenuated Vaccines
- Conjugate Vaccines
- Inactivated Vaccines
- Recombinant Vector Vaccines
- Toxoid Vaccines
- Synthetic Vaccines
- Dendritic Cell Vaccines
- Type
- Preventive Vaccines
- Therapeutic Vaccines
- Disease Indication
- Cervical cancer
- Others
- End user
- Pediatrics
- Adults
- Geography
- South Africa
- Saudi Arabia
- Qatar

According to the World Health Organization, 14-million incidences of cancer and 8.2-million cancer deaths were recorded in 2012. Lung, prostate, colorectal, cervical, and breast cancers remain the most common forms of cancer. Thus, there is a rise in demand for vaccines to prevent and treat cancers

Some of the key participants in the industry include Prima BioMed, GlaxoSmithKline, Sanofi S.A, Merck, Aduro BioTech, AstraZeneca plc, OXFORD BIOMEDICA etc.


- Increasing cancer cases
- Technological developments
- Drug innovations with regard to the cancer
- Government initiatives
- Rise in aging populace
- Advanced health care services
- Upsurge in awareness about cancer and their available therapies in the market
- Increasing health care expenditure


- Cold chain, or temperature-controlled supply chain, management
- Low accessibility to vaccines in remote areas
- Stringent regulatory procedures

Please note: As this product is updated at the time of order, dispatch will be 72 hours from the date the order and full payment is received
Note: Product cover images may vary from those shown
2 of 5


  • Aduro Biotech
  • Cytos
  • GlaxosmithKline
  • Medimmune
  • Oxford Biomedica
  • Sanofi
  • MORE
1. Executive Summary
2. Research Methodology
3. Introduction
3.1 Report Description
3.2 Markets Covered
4. Market Overview
4.1 Market Definition
4.2 Market Drivers
4.2.1 Increased Prevalence of Cancers
4.2.2 Rising Government and Non-Government Funding for Vaccine Development
4.2.3 Increasing Investments By Companies
4.2.4 Technological Advancements
4.3 Market Restraints
4.3.1 Cold Chain Management
4.3.2 Huge Capital Investments
4.3.3 Stringent Regulatory Procedures
4.4 Market Opportunitites
4.5 Market Threats
5. Porters Five Force Analysis
5.1 Bargaining Power of suppliers
5.2 Bargaining power of buyers
5.3 Degree of competition
5.4 Threat of substitution
5.5 Threat of new entrants
6. Market Segmentation
6.1 By Technology
6.1.1 Subunit Vaccines
6.1.2 Live Attenuated Vaccines
6.1.3 Conjugate Vaccines
6.1.4 Inactivated Vaccines
6.1.5 Recombinant Vector Vaccines
6.1.6 Toxoid Vaccines
6.1.7 Synthetic Vaccines
6.1.8 Dendritic Cell Vaccines
6.2 By Type
6.2.1 Preventive Vaccines
6.2.2 Therapeutic Vaccines
6.3 By Disease Indication
6.3.1 Cervical cancer
6.3.2 Others
6.4 By End User
6.4.1 Pediatrics
6.4.2 Adults
6.5 By Geography
6.5.1 South Africa
6.5.2 Saudi Arabia
6.5.3 Qatar
7. Competitive Landscape
7.1 Mergers & Acquisitions
7.2 Agreements, Collaborations & Partnerships
7.3 New Product Launches
7.4 Recommendations to new market players
7.5 Value Chain Analysis
8. Company Profiles
8.1 AstraZeneca plc
8.2 Aduro BioTech
8.3 Cytos
8.4 Galena Biopharma
8.5 Juvaris Biotherapeutics
8.6 MedImmune
8.7 Oxford BioMedica
8.8 Prima BioMed
8.9 GlaxoSmithKline
8.10 Sanofi
8.11 Merk&co
8.12 Ubivac
8.13 Vaccinogen
9. Appendix
9.1 Abbrevations
9.2 Sources
9.3 Bibliography
9.4 Disclaimer
Note: Product cover images may vary from those shown
3 of 5


4 of 5
AstraZeneca Plc
Aduro Biotech
Galena Biopharma
Juvaris Biotherapeutics
Oxford Biomedica
Prima Biomed
Merck & Co.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown